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Prospective isolation is critical for understanding the
cellular andmolecular aspects of stem cell heteroge-
neity. Here, we identify the cell surface antigen CD9
as a positive marker that provides a simple alterna-
tive for hematopoietic stem cell isolation at high
purity. Crucially, CD9 affords the capture of all
hematopoietic stem cells in murine bone marrow in
the absence of contaminating populations that lack
authentic stem cell function. Using CD9 as a tool to
subdivide hematopoietic stem-cell-containing popu-
lations, we provide evidence for heterogeneity at the
cellular, functional, and molecular levels.
INTRODUCTION
The ability to prospectively isolate discrete hematopoietic cell
fractions has afforded the identification and functional analysis
of hematopoietic stem and progenitor cells, allowing for detailed
descriptions of the hierarchical organization of the hematopoiet-
ic system as well as of the transcriptional programs regulating
commitment steps. The resulting road map of hematopoiesis
provides a platform for the description of malignant target cells
and molecular regulation of leukemogenesis. However, isolation
of hematopoietic cell fractions is an ongoing process of refine-
ment at both the progenitor and stem cell levels (Balazs et al.,
2006; Kiel et al., 2005; Ooi et al., 2009; Pronk et al., 2007).
Hematopoietic stem cells (HSCs) have been best character-
ized in murine bone marrow (BM) and are defined by their ability
to self-renew and differentiate in a manner that can support the
hematopoietic system throughout life. Cells with this capacity
are generally referred to as long-term HSCs, which distinguishes
them from the so-called short-term HSCs that possess limited
self-renewal capacity and transient multilineage repopulation
ability. The potential of HSCs is perhaps best demonstrated by
the ability of at least a fraction of putative HSCs to reconstitute
the entire hematopoietic system in single-cell transplants (Kiel642 Cell Reports 4, 642–648, August 29, 2013 ª2013 The Authorset al., 2005; Osawa et al., 1996). The most commonly used
methods purifying these cells involve fluorescence-activated
cell sorting (FACS), using antibody combinations against lineage
markers, stem-cell antigen (Sca)-1, and c-kit (LSK) further subdi-
vided by either Fms-like tyrosine kinase receptor 3 (Flt3) and
CD34 (LSKFlt3-CD34-) or Slam markers (LSKCD48CD150+) (Adolfs-
son et al., 2001, 2005; Kiel et al., 2005; Osawa et al., 1996;
Yang et al., 2005). Alternative strategies based on physical
attributes of HSCs have also been reported (Goodell et al.,
1996). Regardless of purification strategy, considerable hetero-
geneity remains in the HSC compartment, including variations
in reconstitution kinetics, lineage output, and self-renewal
potential (Copley et al., 2012).
Despite the considerable benefit current strategies have had
for our understanding of HSC biology and the recent advances
to these protocols through the addition of positive markers like
EPCR and ESAM-1 (Balazs et al., 2006; Ooi et al., 2009), the
cellular basis for HSC heterogeneity is still unclear. More specif-
ically, the extent to which this relates to the presence of contam-
inating non-HSCswithin the putative HSC populations, relates to
the existence of true functional variation within the HSC pool, or
is due to stochastic transcriptional noise within functionally
similar HSCs remains elusive. Resolving these matters would
be greatly facilitated by capturing all HSCs in the marrow and
analyzing their functional and molecular biology at both popula-
tion and single-cell levels. To this end, herein we identify CD9 as
a tool for such studies and dissect heterogeneity within theHSCs
defined by CD9 expression.
RESULTS AND DISCUSSION
CD9 Is a Positive Marker that Simplifies Prospective
Isolation of HSCs
By global gene expression profiling of a BM-derived multipotent
hematopoietic progenitor cell line, we have previously identified
CD9 as a candidate marker for primitive hematopoietic cells
(Bruno et al., 2004). Analyses of primary cells are consistent
with this notion, demonstrating the highest CD9 levels in the
HSC fraction (Figure S1) and raising the possibility that CD9
Figure 1. CD9 Allows for Simplified Purification of HSCs
(A) Sorting strategy and analysis for HSC markers of LS cells subdivided by CD9 expression.
(B and C) Donor contribution (B) and mean lineage distribution (C) in recipients transplanted with 40 CD9high or 100 CD9low LS cells. Each dot represents one
recipient, n = 3.
(D) Estimation of CRU frequency in CD9high LS cells based on limiting dilution transplantations using the indicated cell doses.
(E) Sorting strategy for CD48CD9high cells and FACS analysis for HSC markers. In certain experiments, where c-kit enrichment is not as efficient, lineage
depletion is necessary to achieve these results. It is, then, a simple matter to include a lineage cocktail in the CD48 channel.
(F and G) Donor contribution (F) and lineage distribution (G) in recipients transplanted with 20 CD48CD9high cells.
See also Figures S1 and S4.can be used for purification of HSCs. We therefore tested
whether inclusion of CD9 as a positive selection marker could
replace a number of other markers currently included in existing
strategies, thereby simplifying prospective isolation of HSCs.
Following lineage depletion and Sca-1 selection (LS) to exclude
CD9-expressing progenitor populations (Figures S1 and S4),
CD9high cells showed an identical phenotype to HSCs isolated
by the more complex existing strategies (Figure 1A; Table S1).
Moreover, >90% of the CD9high LS cells lacked intracellular
expression of the proliferation marker Ki67, suggesting that
they are in the quiescent, G0 phase of the cell cycle, a docu-
mented trait of HSCs (Cheshier et al., 1999) (Figure S1). Of
note, CD9high cells read out as functional HSCs in transplantation
assays and long-term reconstituting multiple hematopoietic line-
ages in primary recipients (Figures 1B and 1C), as well as over
serial transplantation (data not shown). Limiting dilution trans-
plantations further revealed similar HSC frequencies in theCD9high LS population as have been reported for populations
purified by ‘‘conventional methods’’ (Kiel et al., 2005; Osawa
et al., 1996) (Figure 1D). In contrast, CD9low cells neither pheno-
typically nor functionally resemble HSCs. Taken together, our
data demonstrate that CD9 can simplify prospective isolation
of HSCs without loss of purity.
In deconstructing our strategy, we noted that further simplifi-
cation could be made possible. C-kit enriched, CD48, CD9high
BM cells were negative for lineage markers and displayed an
immunophenotypic HSC signature (Figure 1E). Additionally,
low doses of CD48CD9high cells gave robust long-term multili-
neage reconstitution in all recipients transplanted (Figures 1F
and 1G), suggesting that HSCs could be isolated at high purity
using only two channels.
In summary, CD9 significantly simplifies high-purity isolation
of HSCs. This allows for HSC analysis when FACS or sorting
possibilities are limited, as well asmore advanced FACS analysisCell Reports 4, 642–648, August 29, 2013 ª2013 The Authors 643
Figure 2. CD9 Captures All HSCs at High Purity and Is a Useful Tool for Exploring Their Functional Heterogeneity
(A and B) Representative plots for the sorting of HSC populations on the basis of LSKCD48CD150 (A) and LSKFlt3CD34 (B) staining further subdivided on the basis of
CD9 expression.
(C) Sixteen-week donor contribution in recipients transplanted with HSCs purified with the indicated markers and subdivided based on expression of CD9. Each
dot represents one recipient, and the graph illustrates data from two to four independent experiments.
(D) Mean lineage distribution in donor-derived peripheral blood presented in (C). Error bars represent SEM. The asterisk indicates a significant difference in
reconstitution to the myeloid lineages (p < 0.05).
(E) Sixteen-week lineage distribution in recipients transplanted with 10 CD9high LSKCD48CD150 cells.
(F) Reconstitution frequencies in limiting dilution transplantations using CD9high LSKCD48CD150 cells at the indicated cell doses.
See also Figures S2 and S4.on high-purity HSC populations, as three to four channels are
freed for other markers.
CD9 Captures All HSCs in Murine BM
Stringent use of available markers already allows for high purity
prospective isolation of HSCs. However, accumulating reports
suggest that this comes at the expense of yield, and rare long-
term reconstitution activity has been observed also in transplan-
tation studies of both CD34+ and CD150 populations (Challen
et al., 2010; Osawa et al., 1996;Weksberg et al., 2008).We there-
fore asked whether CD9 could capture all HSCs in murine BM.
To this end, we utilized CD9 to subdivide conventional popula-
tions known to contain HSCs and transplanted these into irradi-644 Cell Reports 4, 642–648, August 29, 2013 ª2013 The Authorsated recipient mice (Figures 2A, 2B, and S4; Table S1). The over-
lap between immunophenotypic HSC populations is presented
in Figure S2. Interestingly, all HSC activity was detected in the
CD9high fractions, while no long-term engraftment to multiple
lineages was detected in mice transplanted with CD9low cells,
except for in one outlier mouse (Figure 2C).
The capture of all HSCs at high purity further facilitates explo-
ration of different aspects of HSC heterogeneity. Indeed, lineage
distribution analysis indicated myeloid and lymphoid biases
between CD150+ and CD150 HSCs, respectively (Figure 2D).
Specifically, lymphoid bias was detected in recipients trans-
planted with CD9high LSKCD48CD150 cells (Figure 2D). Our
data suggest that this represents a self-renewing population
Figure 3. Single-Cell Transcriptional Profiling Reveals Cellular Heterogeneity within HSC Populations
(A) Single-cell gene expression analysis of CD9high LSKFlt3CD34 (n = 70) and LSKFlt3CD34+ (n = 72) cells, as well as CD9low LSKFlt3CD34 (n = 71) and
LSKFlt3CD34+ (n = 65) cells. Each row represents one cell. Genes are color coded according to the category they represent. The data show color representation of
the inverted standard score of change in cycle threshold values normalized to three reference genes (Atp5a1, Hprt, and Actb).
(B) PCA of the data presented in (A). Each dot represents a cell and is color coded based on its immunophenotype as indicated in (A).
(C) FACS analysis of intracellular Ki67 expression in LSK cells further subdivided as indicated (n = 2). Error bars represent SEM.
(D) Day 3 colony-forming assay for CFU-E potential of the LSKFlt3CD34 population subdivided by CD9 (n = 2). Error bars represent SEM.
(E) Determination of the skew in expression means of Epor and Ki67 in HSCs. The mean of each gene in the LSKFlt3CD34 HSC population was calculated based
on randomly sampled CD9high and CD9low cells to a ratio of 2.6:1 and was repeated 1,000 times to draw a distribution (box plot) against which the means (colored
lines) from the CD9-enriched populations could be compared. Expression levels are relative to the housekeeping genes.
See also Figure S3.with a high frequency of lymphoid-biased cells since lineage
skewing was maintained over serial transplants (Figure S2) and
exacerbated when transplanting low doses of cells in limiting-
dilution experiments (Figures 2E and 2F). Thus, CD9 is a useful
tool for dissecting true functional HSC heterogeneity with
respect to lineage bias within HSCs, a feature of HSCs that
has recently come to the fore (Challen et al., 2010; Kent et al.,
2009; Weksberg et al., 2008).
CD9Affords Analysis ofMolecular Heterogeneity in HSC
Populations
CD9 allows for discrimination of bona fide HSCs from contami-
nating nonreconstituting cells within established HSC compart-
ments, as well as capture of HSCs from cell fractions where
they are thought to be rare. Thus the ‘‘conventionally sorted’’
long-term reconstituting HSC population (LSKFlt3CD34) as
well as the ‘‘conventional’’ short-term reconstituting HSCs
(LSKFlt3CD34+) may be subdivided on the basis of CD9, yieldingfour cell fractions with distinct immunophenotype and function.
Having these at hand affords reinvestigation of transcriptional
programs from different HSC fractions both at population level
and at single-cell level. To this end, we performed single-cell
quantitative multiplex reverse transcriptase (RT)-PCR analysis
on a microfluidics-based platform for a preselected set of 36
genes documented as markers or functional regulators for
HSCs, lineage commitment, or cell cycle (Figure 3A). The primary
data (Figure 3A) and the principal-component analysis (PCA; Fig-
ure 3B) highlight not only the relationship between these different
compartments but also the heterogeneity within them. An over-
whelming proportion of cells from the CD9high fraction of the
long-term reconstituting HSC population (LSKFLT3CD34) ex-
pressed HSC-related genes, while Ki67 and cyclins critical for
cell cycle were silent. Of the lineage markers assayed, only
scattered expression of megakaryocyte-erythroid genes was
observed (Figure 3A). In contrast, expression of HSC genes
was infrequent among CD9low cells of this fraction, while Ki67Cell Reports 4, 642–648, August 29, 2013 ª2013 The Authors 645
Figure 4. High-Resolution Global Gene
Expression Analyses andMolecular Hetero-
geneity within Single HSCs
(A) Dot plot of RNA-seq analysis: blue dots
represent genes that failed to pass quality filtering;
red and green dots represent genes with more
than 2-fold higher or lower expression in LT-HSCs,
compared to ST-HSCs, respectively.
(B) RNA-seq data from genes expected to be
deregulated between the LT- and ST-HSCs. Error
bars represent SEM.
(C and D) Validation of the RNA-seq data by
single-cell qPCR analysis of genes with varying
upregulation in LT-HSCs presented at single-cell
level (C) and as mean expression (D). Error bars
represent SEM.
(E) Single-cell gene expression data of transcrip-
tional regulators that were upregulated in LT-
HSCs using both RNA-seq and qPCR analysis.
The data in (C) and (E) show color representation
of inverted standard score of DCT values normal-
ized to three reference genes (Atp5a1, Hprt,
and Actb).
See also Tables S2 and S3.and cyclins were upregulated. It is striking that, among the
CD9low cells, 61% (44/72) of the cells expressed erythropoietin
receptor (Epor) and a largemajority of the Epor+ cells additionally
expressed the two other erythroid regulators, Scl/Tal1 and
Gata1, while lacking messenger RNA (mRNA) for Cd34 and
Mpl (Figure S3). In support of the molecular data suggesting
erythroid-lineage character, CD9low cells generated late
erythroid colony-forming units (CFU-Es), with efficiency close
to that of prospectively isolated CFU-E cells (Figure 3D; data
not shown) (Pronk et al., 2007), while displaying poor colony-
forming capacity for other myeloid progenitors (Figure S3).
Thus, single-cell molecular profiling supports our functional
data in that HSCs are exclusively found in the CD9high fraction
of the HSC population. CD9low cells represent a nonreconstitut-
ing, contaminating progenitor population with mainly erythroid
potential. Thus, CD9 affords resolution of cell heterogeneity
resulting from copurification of lineage-committed cells with
bona fide HSCs.646 Cell Reports 4, 642–648, August 29, 2013 ª2013 The AuthorsOur studies of CD9-enriched HSCs
reveal a more transcriptionally coherent
picture within HSCs than has been pre-
viously described (Ma˚nsson et al.,
2007). PCA of the single-cell gene
expression data reveal that 55/100
(1/1.8) LSKFLT3CD34 cells share a
similar HSC molecular signature (Fig-
ure 3B). CD9high enrichment of this pop-
ulation purifies this signature to 1/1.3
cells (53/70). Of note, this exclusion of
molecularly dissimilar non-HSCs has
substantial effect on gene expression
analysis at population level, exemplified
by the 2.7- and 3.9-fold downregula-
tion of Epor and Ki67 expression,respectively, following further enrichment of HSCs by CD9
(Figure 3E).
Within the ‘‘conventionally sorted’’ short-term reconstituting
HSC population (LSKFLT3CD34+), CD9high cells had a transcrip-
tional pattern similar to that of the HSCs described earlier (i.e.,
CD9high LSKFLT3CD34), with HSC-related genes frequently
expressed. However, this population contains a substantial pro-
portion of cells expressing genes involved in cell cycle progres-
sion. FACS analysis confirmed that a difference in Ki67 expres-
sion discriminated between the different populations, where
>90% of CD9high LSKFLT3CD34 cells were Ki67, compared
to only 50% of the other CD9high HSC population, as well as
the CD9low cells (Figure 3C). Thus, CD9 identifies functional het-
erogeneity within the HSC population relating to cell cycle status
and allows for resolution of a proliferating HSC population ex-
pressing the activation marker CD34 (Sato et al., 1999). Of
note, the recently identified HSC marker EPCR (Procr) (Balazs
et al., 2006) was infrequently expressed in this repopulating
compartment, suggesting discrepancy between CD9 and EPCR
expression (Figure 3A).
Again, the CD9low fraction of LSKFLT3-CD34+ cells presented an
entirely different transcriptional pattern than that of CD9high cells,
displaying a largely silent HSC signature, while myeloid-corre-
lating genes such as Mpo and Cebpa are expressed at higher
frequencies (Figure 3A).
Thus, it is clear that further separation based on CD9 expres-
sion discriminates transcriptional profiles that were previously
merged (Ma˚nsson et al., 2007) and that most instances of detec-
tion of lineage-affiliated markers occur in CD9low non-HSCs
rather than in CD9high HSCs. This is in line with our recent find-
ings on individual cells from self-renewing cell lines where
large-scale expression of lineage programs and self-renewal
capacity were separated (Pina et al., 2012).
Taken together, the ability to discriminate authentic HSCs
from nonreconstituting cells affords analysis of true molecular
HSC signatures, without the confounding variable of contami-
nating cells. This elimination of cellular heterogeneity resulting
from copurification of non-HSCs gives insight into the transcrip-
tional programs underlying stem cell function and further
uncovers functional heterogeneity within the HSC pool.
High-Resolution RNA-Seq Analysis of CD9high HSCs
Reveals Molecular Heterogeneity on a Single-Cell Level
The capacity to dissect heterogeneity prompts a reinvestigation
of global gene expression programs of prospectively isolated
HSCs. We therefore performed RNA sequencing (RNA-seq) an-
alyses of a highly purified and functionally homogenous HSC
population (LT-HSCs; LSKCD48CD150+CD34CD9high), depleted
of lymphoid- and cell-cycle-biased HSCs. We compared this
transcriptome with that of a primitive progenitor population lack-
ing HSCs, but with low-engrafting, short-term multilineage
reconstituting activity in our transplantation experiments (ST-
HSCs; LSKCD48CD150+CD9low; data not shown). In two indepen-
dent experiments, approximately 55 3 106 reads were aligned
to the mouse genome. A total of 9,152 genes survived quality
control and were analyzed for differential expression between
LT- and ST-HSCs (Figure 4A). Genes such as Mki67, Cdkn1c
(p57), and CD34 displayed substantial differential expression
as expected (Figure 4B), while gene set enrichment analysis re-
vealed significant overrepresentation of cell cycle genes within
the ST-HSC sample, confirming the success of LT-/ST-HSC
expression profiling by RNA-seq despite the observed and ex-
pected close relation between the two populations analyzed.
We compiled a refined stem cell signature by identifying genes
with >2-fold differential expression between compartments in
both experiments: 241 genes were found to be upregulated in
LT-HSCs, while 353 had increased expression in ST-HSCs (Fig-
ure 4A; Tables S2 and S3). Of eight differentially expressed
genes at a range of fold changes analyzed, seven were validated
as differentially expressed and also by the single-cell RT-quanti-
tative PCR (qPCR) method (Figures 4C and 4D). We used the
Gene Ontology database to identify a total of 22 differential
genes involved in regulation of transcription. Of these, 18 were
selected for single-cell qPCR analysis to obtain a measure of
transcriptional homogeneity among HSCs. It is interesting that,
among the 11 genes identified as upregulated in LT-HSCs, twodistinct patterns of expression emerged. (1) Twenty-seven
percent of genes were expressed in most cells in both popula-
tions, albeit at higher levels in the individual LT-HSCs (Ciao1,
Taf1b, and FoxO1); (2) the remaining 73% changed in frequency,
although not in level, indicating heterogeneous expression of a
subset of transcripts (Batf2, Epas1, Klf2, Rarg, Rorc, Runx1t1,
Smad7, and Tgfb1i1; Figure 4E). Thus, although LT-HSCs are
nearly homogeneous in functional terms and share a similar tran-
scriptional signature with several genes (e.g., Vwf, Tenc)
uniquely expressed in virtually all LT-HSCs (Figures 3A and
4C), a snapshot view of transcription factor expression reveals
striking molecular heterogeneity of a fraction of genes. Thus,
even after depletion of non-HSC progenitors, there is still consid-
erable transcriptional noise and fate priming within the function-
ally largely homogenous HSCs.
EXPERIMENTAL PROCEDURES
Mice
C57Bl/6 (CD45.2), congenic B6SJL (CD45.1), and C57Bl/6 3 B6SJL (CD45.1/
CD45.2) mice were kept in ventilated racks and given autoclaved food and
water in the barrier facility at the Biomedical Center of Lund University. All
animal experiments were approved by the Lund University Animal Ethical
Committee.
FACS Analysis and Sorting
Peripheral blood, unfractionated BM, or magnetically c-kit-enriched BM from
9- to 16-week-old mice was stained in PBS/fetal calf serum (FCS), with com-
binations of antibodies listed in Table S1. For cell cycle analysis, BM stained
with the desired antibody cocktail was fixed with paraformaldehyde (Sigma),
permeabilized with Triton-X (Sigma), and then stained with Ki67 (BD
Biosciences). Cells were sorted on a FACSAriaI cell sorter (BD Biosciences)
or analyzed on a FACSCanto II (BD Biosciences) or a Gallios (Beckman
Coulter) flow cytometer.
Colony Assays
A total of 60–400 cells were sorted into Iscove’s modified Dulbecco’s medium
(Gibco) containing 5%FCS and transferred to 35mmPetri dishes inmethylcel-
lulose medium (M3434; STEMCELL Technologies) supplemented with 100 U/
ml penicillin and 100 mg/ml streptomycin. CFU-Es were scored 3 days
following plating, and other colonies were scored at day 12.
Transplantation Assays
Purified cells were sorted at indicated doses andmixed with 23 105 unfractio-
nated support BM cells from a congenic strain. The cell suspension was trans-
planted into the tail vein of lethally irradiated (900 cGy) recipients. If not stated,
20 cells per recipient were transplanted for LSKCD48150+, LSKFlt3CD34, and
CD48CD9high populations; 100 cells per recipient were transplanted for
CD9low LS cells, LSKCD48150, and LSKFlt3CD34+, and 40 cells per recipient
were transplanted for CD9high LS cells. In limiting dilution assays for the LS9high
or LSK CD48CD150 populations, a recipient mouse was considered to be
reconstituted if donor chimerism was >0.1% for both the myeloid and
lymphoid lineages or only the lymphoid lineages, respectively (Figure S1).
Competitive repopulating unit (CRU) frequency was calculated on the basis
of negative recipients using L-calc software (StemCell Technologies).
Single-Cell qPCR Analysis
Single cells were sorted into lysis buffer containing 0.4% NP40, deoxynucleo-
side triphosphates, dithiothreitol, and RNase OUT (Invitrogen) and snap
frozen. On thawing, CellsDirect reaction mix containing SSIII/PlatinumTaq
(CellsDirect One-Step RT_qPCR kit, no ROX, Invitrogen) and 48 TaqMan
assays to a final dilution of 0.053 each were added to the cell lysate for
RT-PCR preamplification and gene expression quantification according to
previously published protocols (Pina et al., 2012).Cell Reports 4, 642–648, August 29, 2013 ª2013 The Authors 647
RNA-Seq
RNA from 2,000 sorted cells was processed using the SMARTer cDNA syn-
thesis kit (Clontech). End repair was performed on the resulting DNA using
Klenow and T4 PNK. A 30 protruding A base was generated using Taq polymer-
ase, and adapters were ligated. The DNA was loaded on gel, and a band cor-
responding to 300 base pairs (bp) (chromatin immunoprecipitation fragment
plus adapters) was excised. The DNA was isolated, amplified by PCR, and
used for cluster generation on the Illumina 1G genome analyzer (Illumina,
Inc). The 35 bp tags were mapped to the mm9 version of the mouse genome,
and reads within exons were quantified using SeqMonk. Reads within exons
belonging to a single gene were summed to give total gene expression.
Gene expression values were normalized to per-106 tags and converted to
log2. Fold changes were calculated between matched LT- and ST-HSC pairs.
Genes were called differentially expressed whenmore than 2-fold upregulated
or downregulated in both paired sets. For Gene Set Enrichment Analysis
(GSEA) (Subramanian et al., 2005), genes were ranked by fold change and
imported into the GSEA v2.0 software, against which classes from the Gene
Ontology were tested.
ACCESSION NUMBERS
The RNA-seq data have been deposited in the NCBI Gene Expression
Omnibus (GEO) (http://ncbi.nlm.nih.gov/geo) and can be found at accession
number GSE47707.
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